Welcome to our dedicated page for EUDA Health Holdings news (Ticker: EUDA), a resource for investors and traders seeking the latest updates and insights on EUDA Health Holdings stock.
EUDA Health Holdings Limited reports developments across non-invasive and preventive healthcare in Asia, with a focus on Singapore, Malaysia and China. Company updates include longevity and personalized healthcare services, regenerative medicine access, stem cell extraction and cryogenic storage, and commercial arrangements for selected cellular immunotherapies, including TCR-T-related therapies supplied through Shenzhen Inno Immune.
EUDA announcements also cover public-company capital actions and Nasdaq listing matters. Recent corporate developments include ordinary-share adjustments, warrant amendments and cancellations, registered share offerings, and governance actions tied to its capital structure as a Nasdaq-listed foreign private issuer.
EUDA Health (NASDAQ: EUDA) announced that its subsidiary, Melana International, was named one of the winners of the SME100 Awards 2026 Singapore, organized by Business Media International. The SME100 program, audited by Baker Tilly Singapore, evaluates small and medium-sized enterprises on revenue growth, business strategy, market presence and innovation.
According to EUDA Health, Melana, founded in 2000, has about 25 years of experience in Singapore’s property management sector and currently manages 31 properties comprising 5,675 residential and commercial units. The recognition reflects Melana’s capabilities in property and strata management, including its work under Singapore’s Building Maintenance and Strata Management Act and support for Management Corporation Strata Titles in estate defect matters. The SME100 honor follows several other 2026 accolades for Melana, such as the Sustainable Brand Awards, Business Trust Award, Singapore SME Leadership & Achievement Awards, and Singapore Trusted Quality Brand.
EUDA Health (NASDAQ: EUDA) has outlined an integrated cell therapy program under a non-binding Memorandum of Understanding signed on July 15, 2026 with GO POSB Organoids and Shenzhen Innovation Immunotechnology (SIIT). The parties plan, subject to definitive agreements and regulatory approvals, to combine GO POSB’s proprietary induced pluripotent stem cell (iPSC) platform and clinical-grade universal tumor organoid bank with SIIT’s Natural Killer (NK) and NK-TCR cell engineering capabilities and GMP manufacturing to explore future development of off-the-shelf cell therapies for wellness and oncology.
According to EUDA, it intends to fund the collaboration, bring GO POSB and SIIT together, facilitate commercialization and support global market access. GO POSB plans to provide access to its iPSC platform and organoid bank, while SIIT plans to supply NK/NK-TCR engineering, iPSC differentiation, genetic engineering, maturation, GMP manufacturing and testing. All contemplated technologies remain investigational and any commercialization will depend on sufficient funding, completion of development and required regulatory approvals.
EUDA Health (NASDAQ: EUDA) announced a tri-party Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on next-generation therapies derived from induced pluripotent stem cells (iPSC).
The MOU outlines intentions to co-develop, manufacture and commercialize off-the-shelf oncology cell therapies for cancer treatment and wellness applications, supporting EUDA Health’s strategy to expand its portfolio of science-backed wellness and non-invasive healthcare products and services in Singapore, Malaysia and China.
EUDA Health (NASDAQ:EUDA) is expanding its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, developed by Chemokine. EUDA holds exclusive global distributorship rights for Helixé and plans to leverage distribution networks in Malaysia and China to grow sales across Asia-Pacific.
The Regenixé Mask uses iPSC-derived skin stem cell secretome and cellulose mask technology aimed at supporting skin hydration, brightening, and recovery. According to Mordor Intelligence, the global face mask market is projected to grow from about US$7.95 billion in 2026 to US$9.08 billion by 2031, with Asia-Pacific a key region.
EUDA Health (NASDAQ:EUDA), a Singapore-based non-invasive healthcare provider focused on Singapore, Malaysia and China, received notice on May 28, 2026 that it has regained compliance with Nasdaq’s Minimum Market Value of Listed Securities requirement.
EUDA’s MVLS was at least $35 million for ten consecutive business days from May 13–27, 2026, restoring eligibility for continued listing on the Nasdaq Capital Market.
EUDA (NASDAQ: EUDA) announced that Shenzhen Inno Immune received approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T therapy project running Jan 1, 2026–Dec 31, 2028. The Bureau may provide funding of up to approximately US$434,688. EUDA holds non-exclusive rights to market and sell selected Shenzhen Inno immunotherapies in Malaysia via subsidiary CK Health Plus Sdn Bhd, with treatments to be conducted in China. The project targets solid tumors using AI-driven antigen screening, enhanced TCR engineering, and exploratory clinical studies in collaboration with Shenzhen research institutions and Shenzhen People’s Hospital.
EUDA Health Holdings (NASDAQ:EUDA) received a Nasdaq notice dated April 23, 2026, that it failed to maintain a $35.0 million Minimum Market Value of Listed Securities (MVLS) over the last 32 consecutive business days.
The MVLS notice does not affect the current listing immediately. The company has a 180-calendar-day compliance period ending October 20, 2026, to close at $35,000,000 or more for ten consecutive business days to regain compliance; failure could lead to delisting proceedings and a possible appeal.
EUDA Health Holdings (NASDAQ: EUDA) will implement a 1-for-20 reverse stock split, effective at market open on March 23, 2026. The split was approved by the board under British Virgin Islands law and the post-split CUSIP will be G3142E147.
Outstanding shares are expected to convert from approximately 50,307,491 to about 2,515,375 shares. Warrants will be adjusted proportionately: aggregate warrants remain 8,917,250, reducing issuable shares from 4,458,625 to about 222,932, and the warrant exercise price will change from $11.50 (per half-share basis) to $230.00 per warrant. No fractional shares or cash will be issued for fractions; holdings will be rounded up.
EUDA Health Holdings (NASDAQ: EUDA) repurchased and cancelled in full a warrant issued to Streeterville Capital, eliminating the potential issuance of up to 2,000,000 ordinary shares. The warrant was repurchased on February 27, 2026 for a total purchase price of US$125,000.
As a result, there are no warrants remaining under the November 26, 2025 securities purchase agreement and the related potential dilution has been fully removed.
EUDA Health (NASDAQ: EUDA) announced a second amendment to its Streeterville warrant agreement dated January 13, 2026. The amendment reduces the warrant exercise price from US$4.00 to US$2.00 and lowers the forced-exercise minimum closing price from US$6.00 to US$3.00. All other warrant terms remain unchanged. Management described the change as a technical adjustment to align terms with current market conditions while preserving capital-structure flexibility and maintaining the company’s strategic focus on preventive health, longevity, and personalised healthcare.